Research progress on the relationship between cuproptosis and breast cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

REN Lilei , ZHAO Xiaobo , GAO Yanchun ,  HOU Lingmi

1. Department of Breast Surgery, Affiliated Hosptial of North Sichuan Medical College, Nanchong, Sichuan 637000, P. R. China;

Corresponding author：

HOU Lingmi, Email: JRWKKY@163.com

Keywords：

cuproptosis; breast cancer; immunotherapy; drug resistance; mechanism

DOI：

10.7507/1007-9424.202309075

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the latest advances in copper and cuproptosis in the field of breast cancer, and to provide a reference for clinical treatment decisions. Method The literatures related to copper and cuproptosis in recent years were read and summarized, and the research progress on the role of copper in breast cancer, the application of cuproptosis in the diagnosis and treatment of breast cancer were reviewed. Results Cuproptosiswas a novel form of programmed cell death, which occurred via direct binding of copper to lipoylated components of the tricarboxylic acid (TCA) cycle, this resulted in lipoylated protein aggregation and subsequent iron-sulfur cluster protein loss, leading to proteotoxic stress and ultimately cell death. Cuproptosis induced proliferation and migration of breast cancer cell , mediated personalized immunotherapy, and participated in endocrine and chemotherapeutic drug resistance. Conclusion Exploring the mechanism of cuproptosis provides potential applications for subsequent immunotherapy, endocrine therapy, and chemotherapy for breast cancer, leading to new effective strategies for patients.

Citation： REN Lilei, ZHAO Xiaobo, GAO Yanchun, HOU Lingmi. Research progress on the relationship between cuproptosis and breast cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2024, 31(2): 250-256. doi: 10.7507/1007-9424.202309075 Copy

1.	Li J, Li L, Dong Y, et al. Comprehensive analysis of cuproptosis genes and identification of cuproptosis subtypes in breast cancer. Comb Chem High Throughput Screen, 2023, 26(8): 1578-1593.
2.	Kim KI, Jang SJ, Park JH, et al. Detection of increased ⁶⁴Cu uptake by human copper transporter 1 gene overexpression using PET with ⁶⁴CuCl₂ in human breast cancer xenograft model. J Nucl Med, 2014, 55(10): 1692-1698.
3.	Brady DC, Crowe MS, Turski ML, et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature, 2014, 509(7501): 492-496.
4.	Baker AM, Bird D, Lang G, et al. Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. Oncogene, 2013, 32(14): 1863-1868.
5.	Zhao Q, Qi T. The implications and prospect of cuproptosis-related genes and copper transporters in cancer progression. Front Oncol, 2023, 13: 1117164. doi: 10.3389/fonc.2023.1117164.
6.	Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J, 1984, 219(1): 1-14.
7.	Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 2022, 375(6586): 1254-1261.
8.	Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res, 2022, 32(5): 417-418.
9.	Lee S, Chung CY, Liu P, et al. Activity-based sensing with a metal-directed acyl imidazole strategy reveals cell type-dependent pools of labile brain copper. J Am Chem Soc, 2020, 142(35): 14993-15003.
10.	Blockhuys S, Celauro E, Hildesjö C, et al. Defining the human copper proteome and analysis of its expression variation in cancers. Metallomics, 2017, 9(2): 112-123.
11.	Ge EJ, Bush AI, Casini A, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer, 2022, 22(2): 102-113.
12.	Ishida S, Andreux P, Poitry-Yamate C, et al. Bioavailable copper modulates oxidative phosphorylation and growth of tumors. Proc Natl Acad Sci U S A, 2013, 110(48): 19507-19512.
13.	和彦苓, 张丽萍, 耿虹, 等. 乳腺癌患者血中铜、锌、硒含量及铜锌比值分析. 包头医学院学报, 2003, 19(3): 179-180.
14.	李莉, 鲁英, 杨晓燕, 等. 新疆乳腺癌患者血清中Mn、Cu、Se、Zn的病例对照研究. 新疆医科大学学报, 2015(1): 67-69.
15.	Tsang T, Posimo JM, Gudiel AA, et al. Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma. Nat Cell Biol, 2020, 22(4): 412-424.
16.	Bengtsson Y, Demircan K, Vallon-Christersson J, et al. Serum copper, zinc and copper/zinc ratio in relation to survival after breast cancer diagnosis: a prospective multicenter cohort study. Redox Biol, 2023, 63: 102728. doi: 10.1016/j.redox.2023.102728.
17.	Jouybari L, Kiani F, Islami F, et al. Copper concentrations in breast cancer: a systematic review and meta-analysis. Curr Med Chem, 2020, 27(37): 6373-6383.
18.	Xie J, Yang Y, Gao Y, et al. Cuproptosis: mechanisms and links with cancers. Mol Cancer, 2023, 22(1): 46. doi: 10.1186/s12943-023-01732-y.
19.	Jiang B, Zhu H, Feng W, et al. Database mining detected a cuproptosis-related prognostic signature and a related regulatory axis in breast cancer. Dis Markers, 2022, 2022: 9004830.
20.	Kong FS, Ren CY, Jia R, et al. Systematic pan-cancer analysis identifies SLC31A1 as a biomarker in multiple tumor types. BMC Med Genomics, 2023, 16(1): 61. doi: 10.1186/s12920-023-01489-9.
21.	Li X, Ma Z, Mei L. Cuproptosis-related gene SLC31A1 is a potential predictor for diagnosis, prognosis and therapeutic response of breast cancer. Am J Cancer Res. 2022, 12(8): 3561-3580.
22.	刘以原. 非编码RNA介导铜死亡相关基因SLC31A1高表达与乳腺癌不良预后和肿瘤免疫浸润相关. 汕头大学, 2022.
23.	Huang T, Liu Y, Li J, et al. Insights into prognosis and immune infiltration of cuproptosis-related genes in breast cancer. Front Immunol, 2022, 13: 1054305. doi: 10.3389/fimmu.2022.1054305.
24.	Sha S, Si L, Wu X, et al. Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer. Front Immunol, 2022, 13: 922780. doi: 10.3389/fimmu.2022.922780.
25.	Cheng T, Wu Y, Liu Z, et al. CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer. Front Immunol, 2022, 13: 970950. doi: 10.3389/fimmu.2022.970950.
26.	余荣凤, 杨永秀. 铜诱导细胞死亡及其在妇科肿瘤中的作用研究进展. 山东医药, 2023, 63(4): 100-103.
27.	Zhang C, Zeng Y, Guo X, et al. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker. Front Genet, 2022, 13: 923737. doi: 10.3389/fgene.2022.923737.
28.	Liu Y, Wang J, Jiang M. Copper-related genes predict prognosis and characteristics of breast cancer. Front Immunol, 2023, 14: 1145080. doi: 10.3389/fimmu.2023.1145080.
29.	Zhu B, Wang S, Wang R, et al. Identification of molecular subtypes and a six-gene risk model related to cuproptosis for triple negative breast cancer. Front Genet, 2022, 13: 1022236. doi: 10.3389/fgene.2022.1022236.
30.	Cai Y, He Q, Liu W, et al. Comprehensive analysis of the potential cuproptosis-related biomarker LIAS that regulates prognosis and immunotherapy of pan-cancers. Front Oncol, 2022, 12: 952129. doi: 10.3389/fonc.2022.952129.
31.	Zhang L, Zhang Y, Bao J, et al. Cuproptosis combined with lncRNAs predicts the prognosis and immune microenvironment of breast cancer. Comput Math Methods Med, 2022, 2022: 5422698.
32.	Zhou Z, Deng J, Pan T, et al. Prognostic significance of cuproptosis-related gene signatures in breast cancer based on transcriptomic data analysis. Cancers (Basel), 2022, 14(23): 5771. doi: 10.3390/cancers14235771.
33.	Li J, Wu F, Li C, et al. The cuproptosis-related signature predicts prognosis and indicates immune microenvironment in breast cancer. Front Genet, 2022, 13: 977322. doi: 10.3389/fgene.2022.977322.
34.	Guo Q, Qiu P, Pan K, et al. Comprehensive analysis of cuproptosis-related long non-coding RNA signature and personalized therapeutic strategy of breast cancer patients. Front Oncol, 2022, 12: 1081089. doi: 10.3389/fonc.2022.1081089.
35.	Song S, Zhang M, Xie P, et al. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer. Front Immunol, 2022, 13: 978909. doi: 10.3389/fimmu.2022.978909.
36.	Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490(7418): 61-70.
37.	Szostakowska M, Trębińska-Stryjewska A, Grzybowska EA, et al. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat, 2019, 173(3): 489-497.
38.	Zhang D, Lu W, Zhuo Z, et al. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer. BMC Med Genomics, 2023, 16(1): 96. doi: 10.1186/s12920-023-01511-0.
39.	Li L, Li L, Sun Q. High expression of cuproptosis-related SLC31A1 gene in relation to unfavorable outcome and deregulated immune cell infiltration in breast cancer: an analysis based on public databases. BMC Bioinformatics, 2022, 23(1): 350. doi: 10.1186/s12859-022-04894-6.
40.	Davis CI, Gu X, Kiefer RM, et al. Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation. Metallomics, 2020, 12(12): 1995-2008.
41.	Chen D, Cui QC, Yang H, et al. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res, 2006, 66(21): 10425-10433.
42.	O’Day SJ, Eggermont AM, Chiarion-Sileni V, et al. Final results of phase Ⅲ SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol, 2013, 31(9): 1211-1218.
43.	Denoyer D, Masaldan S, La Fontaine S, et al. Targeting copper in cancer therapy: 'Copper That Cancer'. Metallomics, 2015, 7(11): 1459-1476.
44.	Ramchandani D, Berisa M, Tavarez DA, et al. Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis. Nat Commun, 2021, 12(1): 7311. doi: 10.1038/s41467-021-27559-z.
45.	Li Y. Copper homeostasis: emerging target for cancer treatment. IUBMB Life, 2020, 72(9): 1900-1908.
46.	Shi H, Suo Y, Zhang Z, et al. Copper(Ⅱ)-disulfiram loaded melanin-dots for cancer theranostics. Nanomedicine, 2021, 32: 102340. doi: 10.1016/j.nano.2020.102340.
47.	Meng X, Shi Y, Chen Z, et al. Extending hypochlorite sensing from cells to elesclomol-treated tumors in vivo by using a near-infrared dual-phosphorescent nanoprobe. ACS Appl Mater Interfaces, 2018, 10(42): 35838-35846.
48.	Cui L, Gouw AM, LaGory EL, et al. Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. Nat Biotechnol, 2021, 39(3): 357-367.
49.	Jiao Y, Hannafon BN, Ding WQ. Disulfiram’s anticancer activity: evidence and mechanisms. Anticancer Agents Med Chem, 2016, 16(11): 1378-1384.
50.	Wang Y, Li W, Patel SS, et al. Blocking the formation of radiation-induced breast cancer stem cells. Oncotarget, 2014, 5(11): 3743-3755.
51.	Wu L, Meng F, Dong L, et al. Disulfiram and BKM120 in combination with chemotherapy impede tumor progression and delay tumor recurrence in tumor initiating cell-rich TNBC. Sci Rep, 2019, 9(1): 236. doi: 10.1038/s41598-018-35619-6.
52.	Liu T, Zhou Z, Zhang M, et al. Cuproptosis-immunotherapy using PD-1 overexpressing T cell membrane-coated nanosheets efficiently treats tumor. J Control Release, 2023, 362: 502-512.
53.	Rauf A, Abu-Izneid T, Khalil AA, et al. Berberine as a potential anticancer agent: a comprehensive review. Molecules, 2021, 26(23): 7368. doi: 10.3390/molecules26237368.
54.	Lee SY, Seo JH, Kim S, et al. Cuproptosis-inducible chemotherapeutic/cascade catalytic reactor system for combating with breast cancer. Small, 2023, 19(35): e2301402. doi: 10.1002/smll.202301402.
55.	Xiong C, Ling H, Hao Q, et al. Cuproptosis: p53-regulated metabolic cell death? Cell Death Differ, 2023, 30(4): 876-884.
56.	Shen Y, Li D, Liang Q, et al. Cross-talk between cuproptosis and ferroptosis regulators defines the tumor microenvironment for the prediction of prognosis and therapies in lung adenocarcinoma. Front Immunol, 2023, 13: 1029092. doi: 10.3389/fimmu.2022.1029092.
57.	陈佩贤, 叶国麟. 乳腺癌患者生存质量研究现状. 中国普外基础与临床杂志, 2021, 28(11): 1510-1515.

1. Li J, Li L, Dong Y, et al. Comprehensive analysis of cuproptosis genes and identification of cuproptosis subtypes in breast cancer. Comb Chem High Throughput Screen, 2023, 26(8): 1578-1593.
2. Kim KI, Jang SJ, Park JH, et al. Detection of increased ⁶⁴Cu uptake by human copper transporter 1 gene overexpression using PET with ⁶⁴CuCl₂ in human breast cancer xenograft model. J Nucl Med, 2014, 55(10): 1692-1698.
3. Brady DC, Crowe MS, Turski ML, et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature, 2014, 509(7501): 492-496.
4. Baker AM, Bird D, Lang G, et al. Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. Oncogene, 2013, 32(14): 1863-1868.
5. Zhao Q, Qi T. The implications and prospect of cuproptosis-related genes and copper transporters in cancer progression. Front Oncol, 2023, 13: 1117164. doi: 10.3389/fonc.2023.1117164.
6. Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J, 1984, 219(1): 1-14.
7. Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 2022, 375(6586): 1254-1261.
8. Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res, 2022, 32(5): 417-418.
9. Lee S, Chung CY, Liu P, et al. Activity-based sensing with a metal-directed acyl imidazole strategy reveals cell type-dependent pools of labile brain copper. J Am Chem Soc, 2020, 142(35): 14993-15003.
10. Blockhuys S, Celauro E, Hildesjö C, et al. Defining the human copper proteome and analysis of its expression variation in cancers. Metallomics, 2017, 9(2): 112-123.
11. Ge EJ, Bush AI, Casini A, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer, 2022, 22(2): 102-113.
12. Ishida S, Andreux P, Poitry-Yamate C, et al. Bioavailable copper modulates oxidative phosphorylation and growth of tumors. Proc Natl Acad Sci U S A, 2013, 110(48): 19507-19512.
13. 和彦苓, 张丽萍, 耿虹, 等. 乳腺癌患者血中铜、锌、硒含量及铜锌比值分析. 包头医学院学报, 2003, 19(3): 179-180.
14. 李莉, 鲁英, 杨晓燕, 等. 新疆乳腺癌患者血清中Mn、Cu、Se、Zn的病例对照研究. 新疆医科大学学报, 2015(1): 67-69.
15. Tsang T, Posimo JM, Gudiel AA, et al. Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma. Nat Cell Biol, 2020, 22(4): 412-424.
16. Bengtsson Y, Demircan K, Vallon-Christersson J, et al. Serum copper, zinc and copper/zinc ratio in relation to survival after breast cancer diagnosis: a prospective multicenter cohort study. Redox Biol, 2023, 63: 102728. doi: 10.1016/j.redox.2023.102728.
17. Jouybari L, Kiani F, Islami F, et al. Copper concentrations in breast cancer: a systematic review and meta-analysis. Curr Med Chem, 2020, 27(37): 6373-6383.
18. Xie J, Yang Y, Gao Y, et al. Cuproptosis: mechanisms and links with cancers. Mol Cancer, 2023, 22(1): 46. doi: 10.1186/s12943-023-01732-y.
19. Jiang B, Zhu H, Feng W, et al. Database mining detected a cuproptosis-related prognostic signature and a related regulatory axis in breast cancer. Dis Markers, 2022, 2022: 9004830.
20. Kong FS, Ren CY, Jia R, et al. Systematic pan-cancer analysis identifies SLC31A1 as a biomarker in multiple tumor types. BMC Med Genomics, 2023, 16(1): 61. doi: 10.1186/s12920-023-01489-9.
21. Li X, Ma Z, Mei L. Cuproptosis-related gene SLC31A1 is a potential predictor for diagnosis, prognosis and therapeutic response of breast cancer. Am J Cancer Res. 2022, 12(8): 3561-3580.
22. 刘以原. 非编码RNA介导铜死亡相关基因SLC31A1高表达与乳腺癌不良预后和肿瘤免疫浸润相关. 汕头大学, 2022.
23. Huang T, Liu Y, Li J, et al. Insights into prognosis and immune infiltration of cuproptosis-related genes in breast cancer. Front Immunol, 2022, 13: 1054305. doi: 10.3389/fimmu.2022.1054305.
24. Sha S, Si L, Wu X, et al. Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer. Front Immunol, 2022, 13: 922780. doi: 10.3389/fimmu.2022.922780.
25. Cheng T, Wu Y, Liu Z, et al. CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer. Front Immunol, 2022, 13: 970950. doi: 10.3389/fimmu.2022.970950.
26. 余荣凤, 杨永秀. 铜诱导细胞死亡及其在妇科肿瘤中的作用研究进展. 山东医药, 2023, 63(4): 100-103.
27. Zhang C, Zeng Y, Guo X, et al. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker. Front Genet, 2022, 13: 923737. doi: 10.3389/fgene.2022.923737.
28. Liu Y, Wang J, Jiang M. Copper-related genes predict prognosis and characteristics of breast cancer. Front Immunol, 2023, 14: 1145080. doi: 10.3389/fimmu.2023.1145080.
29. Zhu B, Wang S, Wang R, et al. Identification of molecular subtypes and a six-gene risk model related to cuproptosis for triple negative breast cancer. Front Genet, 2022, 13: 1022236. doi: 10.3389/fgene.2022.1022236.
30. Cai Y, He Q, Liu W, et al. Comprehensive analysis of the potential cuproptosis-related biomarker LIAS that regulates prognosis and immunotherapy of pan-cancers. Front Oncol, 2022, 12: 952129. doi: 10.3389/fonc.2022.952129.
31. Zhang L, Zhang Y, Bao J, et al. Cuproptosis combined with lncRNAs predicts the prognosis and immune microenvironment of breast cancer. Comput Math Methods Med, 2022, 2022: 5422698.
32. Zhou Z, Deng J, Pan T, et al. Prognostic significance of cuproptosis-related gene signatures in breast cancer based on transcriptomic data analysis. Cancers (Basel), 2022, 14(23): 5771. doi: 10.3390/cancers14235771.
33. Li J, Wu F, Li C, et al. The cuproptosis-related signature predicts prognosis and indicates immune microenvironment in breast cancer. Front Genet, 2022, 13: 977322. doi: 10.3389/fgene.2022.977322.
34. Guo Q, Qiu P, Pan K, et al. Comprehensive analysis of cuproptosis-related long non-coding RNA signature and personalized therapeutic strategy of breast cancer patients. Front Oncol, 2022, 12: 1081089. doi: 10.3389/fonc.2022.1081089.
35. Song S, Zhang M, Xie P, et al. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer. Front Immunol, 2022, 13: 978909. doi: 10.3389/fimmu.2022.978909.
36. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490(7418): 61-70.
37. Szostakowska M, Trębińska-Stryjewska A, Grzybowska EA, et al. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat, 2019, 173(3): 489-497.
38. Zhang D, Lu W, Zhuo Z, et al. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer. BMC Med Genomics, 2023, 16(1): 96. doi: 10.1186/s12920-023-01511-0.
39. Li L, Li L, Sun Q. High expression of cuproptosis-related SLC31A1 gene in relation to unfavorable outcome and deregulated immune cell infiltration in breast cancer: an analysis based on public databases. BMC Bioinformatics, 2022, 23(1): 350. doi: 10.1186/s12859-022-04894-6.
40. Davis CI, Gu X, Kiefer RM, et al. Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation. Metallomics, 2020, 12(12): 1995-2008.
41. Chen D, Cui QC, Yang H, et al. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res, 2006, 66(21): 10425-10433.
42. O’Day SJ, Eggermont AM, Chiarion-Sileni V, et al. Final results of phase Ⅲ SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol, 2013, 31(9): 1211-1218.
43. Denoyer D, Masaldan S, La Fontaine S, et al. Targeting copper in cancer therapy: 'Copper That Cancer'. Metallomics, 2015, 7(11): 1459-1476.
44. Ramchandani D, Berisa M, Tavarez DA, et al. Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis. Nat Commun, 2021, 12(1): 7311. doi: 10.1038/s41467-021-27559-z.
45. Li Y. Copper homeostasis: emerging target for cancer treatment. IUBMB Life, 2020, 72(9): 1900-1908.
46. Shi H, Suo Y, Zhang Z, et al. Copper(Ⅱ)-disulfiram loaded melanin-dots for cancer theranostics. Nanomedicine, 2021, 32: 102340. doi: 10.1016/j.nano.2020.102340.
47. Meng X, Shi Y, Chen Z, et al. Extending hypochlorite sensing from cells to elesclomol-treated tumors in vivo by using a near-infrared dual-phosphorescent nanoprobe. ACS Appl Mater Interfaces, 2018, 10(42): 35838-35846.
48. Cui L, Gouw AM, LaGory EL, et al. Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. Nat Biotechnol, 2021, 39(3): 357-367.
49. Jiao Y, Hannafon BN, Ding WQ. Disulfiram’s anticancer activity: evidence and mechanisms. Anticancer Agents Med Chem, 2016, 16(11): 1378-1384.
50. Wang Y, Li W, Patel SS, et al. Blocking the formation of radiation-induced breast cancer stem cells. Oncotarget, 2014, 5(11): 3743-3755.
51. Wu L, Meng F, Dong L, et al. Disulfiram and BKM120 in combination with chemotherapy impede tumor progression and delay tumor recurrence in tumor initiating cell-rich TNBC. Sci Rep, 2019, 9(1): 236. doi: 10.1038/s41598-018-35619-6.
52. Liu T, Zhou Z, Zhang M, et al. Cuproptosis-immunotherapy using PD-1 overexpressing T cell membrane-coated nanosheets efficiently treats tumor. J Control Release, 2023, 362: 502-512.
53. Rauf A, Abu-Izneid T, Khalil AA, et al. Berberine as a potential anticancer agent: a comprehensive review. Molecules, 2021, 26(23): 7368. doi: 10.3390/molecules26237368.
54. Lee SY, Seo JH, Kim S, et al. Cuproptosis-inducible chemotherapeutic/cascade catalytic reactor system for combating with breast cancer. Small, 2023, 19(35): e2301402. doi: 10.1002/smll.202301402.
55. Xiong C, Ling H, Hao Q, et al. Cuproptosis: p53-regulated metabolic cell death? Cell Death Differ, 2023, 30(4): 876-884.
56. Shen Y, Li D, Liang Q, et al. Cross-talk between cuproptosis and ferroptosis regulators defines the tumor microenvironment for the prediction of prognosis and therapies in lung adenocarcinoma. Front Immunol, 2023, 13: 1029092. doi: 10.3389/fimmu.2022.1029092.
57. 陈佩贤, 叶国麟. 乳腺癌患者生存质量研究现状. 中国普外基础与临床杂志, 2021, 28(11): 1510-1515.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research progress on the relationship between cuproptosis and breast cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content